Clinical Trials Logo

Critical Illness clinical trials

View clinical trials related to Critical Illness.

Filter by:

NCT ID: NCT04279171 Completed - Critical Illness Clinical Trials

Near-death Experience in ICU Survivors

Start date: June 1, 2019
Phase:
Study type: Observational

This observational study aims to describe the incidence of near-death experience (NDE) in patients who survived a critical illness. In order to help determine the potential risk factors of NDE, dissociative status and spirituality are also investigated. Finally, in patients who experienced NDE, a magnetic resonance imaging is performed to search for any structural modifications.

NCT ID: NCT04262531 Completed - Critical Illness Clinical Trials

Body Composition Study in Critically Ill Patients

Start date: July 5, 2019
Phase:
Study type: Observational

This is a single-center prospective observational study that aimed to describe the trajectory of change in body composition among critically ill patients who were able to function independently prior to admission. Ultrasound measurement of the quadriceps muscle and bioelectrical impedance analysis will be conducted at baseline, day 7, day 14 and before ICU discharge. The relationship between the change of body composition and clinical outcomes, activities of daily living and quality of life at 6-month post ICU admission will be investigated. Further, the association between nutritional (energy and protein) intake and change in body composition will also be investigated.

NCT ID: NCT04252027 Completed - Clinical trials for Critically Ill Patients

Therapeutic Drug Monitoring of Fluconazole in Critically Ill Patients

Start date: April 23, 2019
Phase:
Study type: Observational

This prospective study will research the exposure and its variability to fluconazole after longitudinal administration in critically ill patients

NCT ID: NCT04239209 Completed - Critical Illness Clinical Trials

Effect of Intensivist Communication on Surrogate Prognosis Interpretation

Start date: September 27, 2019
Phase: N/A
Study type: Interventional

This study evaluates the effect of physician communication styles on the interpretation of prognosis by family members of chronically-ill patients. Participants were randomized to view one of four videos how depicting different physicians disclose prognosis when physicians expect an ICU patient to die.

NCT ID: NCT04232956 Completed - Influenza Clinical Trials

Invasive Pulmonary Aspergillosis and Severe Influenza

ASPERGIGRIPP
Start date: July 27, 2018
Phase:
Study type: Observational

Invasive pulmonary aspergillosis (IPA) has been reported in critically ill patients with influenza infection with a highly variable incidence between 1 to 21%. Studies investigating IPA in critically ill patients with influenza infection suffer limitations in their methods. It remains unknown whether patients with influenza are more at risk of IPA than other patients hospitalized in intensive care unit and whether patients with influenza who develop IPA have specific risk factors for this infection. Our study aims to determine the incidence of IPA in a large multicenter cohort and to identify risk factors for IPA in these patients.

NCT ID: NCT04228380 Completed - Critical Illness Clinical Trials

Limitations and Mortality in Intensive Care

LIMO
Start date: March 1, 2020
Phase:
Study type: Observational

This is an observational prospective pilot-study that investigates which patient-related variables that predict a decision to limit life sustaining treatments. Some of the variables we were interested in cannot be accessed in registry data, such as frailty scale score and living at home or not. Furthermore we wanted to investigate if the variables that were independently associated with a decision to limit LST were different for critically ill patients with COVID-19 than for critically ill patients with other diagnoses in a Swedish intensive care unit during the pandemic.

NCT ID: NCT04227548 Completed - Clinical trials for Critical Illness Polyneuromyopathy

Reference Values for Compound Muscle Action Potential Amplitude Obtained by Direct Muscle Stimulation

Start date: April 30, 2019
Phase: N/A
Study type: Interventional

Direct muscle stimulation (DMS) method is one of the electrodiagnostic methods used in the diagnosis of critical illness myopathy (CIM) and critical illness neuropathy (CIN). The ratio of amplitude of compound muscle action potential (CMAP) obtained by nerve stimulation (nCMAP) to amplitude of CMAP obtained by DMS (dmCMAP) can be used to differentiate these two diseases. Although not certain, if the ratio is < 0.5, the diagnosis is thought to be consistent with CIN. The ratio > 0.5 is considered to be a finding supporting CIM. The investigators aimed to find the reference values of the ratio from healthy individuals. A monopolar needle electrode was used for DMS. The dmCMAP and nCMAP were recorded with a concentric needle. The ratio was calculated by using amplitudes of dmCMAP and nCMAP obtained from deltoid and tibialis anterior muscles.

NCT ID: NCT04215627 Completed - Critically Ill Clinical Trials

Comparing the PiCCO Monitor to the Non-invasive Biobeat (BB)-316PW in ICU Patients

Start date: December 26, 2019
Phase:
Study type: Observational

The aim of this study is to compare hemodynamic monitoring using the invasive PiCCO device to the BB-613PW wireless, non-invasive PPG-based device, in critically ill patients within the ICU, suffering from hemodynamic instability and in need of vasopressor support. Data will be gathered prospectively and analysed retrospectively.

NCT ID: NCT04201899 Completed - Critically Ill Clinical Trials

HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey

HYPO-P-ICU
Start date: March 9, 2020
Phase:
Study type: Observational [Patient Registry]

The point prevalence survey aims at defining the until now unknown real prevalence of hypophosphatemia (defined as blood phosphate value < 0.8 mmol/l) in international critical care settings

NCT ID: NCT04187534 Completed - Critical Illness Clinical Trials

Critical Care OptimizatIon of Albumin Ordering

RATIONALE
Start date: November 25, 2019
Phase: N/A
Study type: Interventional

Strong evidence suggests that human albumin solutions should not be used for fluid resuscitation except among patients undergoing therapeutic plasmapheresis and select patients with complications of liver cirrhosis (i.e. spontaneous bacterial peritonitis, or large volume ascitic fluid removal). Previous work by the investigators reported albumin use outside these circumstances as a quality improvement opportunity in Alberta ICUs. In 2017, the investigators began a pilot initiative to reduce albumin overuse in 6 ICUs in Alberta. The intervention was developed according to the Theoretical Domains Framework, and consisted of establishing a clinical champion, educating clinicians, changing the process for albumin ordering (albumin-specific order sheet), and providing quarterly audit/feedback data to clinicians on albumin utilization. During the intervention, there was a 41% relative reduction in albumin utilization. However, follow-up data identified problems with sustainability. These sustainability challenges combined with data suggesting high albumin use in other ICUs throughout Alberta have led the current project to build on the pilot initiative to reduce albumin overuse within all adult ICUs in Alberta. The proposed quality improvement intervention will be implemented in 16 adult ICUs using a registry-based, stepped-wedge implementation design that will lean heavily on existing Provincial healthcare infrastructure. The intervention was developed using the Theoretical Domains Framework, and tailored to the unique features of each participating ICU. It will be implemented at the level of ICU. Clusters of 2 ICUs will be assigned to receive the intervention every month such that all ICUs in Alberta will receive the intervention by the end of the implementation period. To evaluate the quality improvement initiative, eCritical will serve as a 'registry' and will be used to capture all clinical and outcome data. The primary outcome will be the proportion of ICU admissions without an evidence-based indication for albumin, prescribed at least 1 unit of albumin (any concentration) during admission to ICU. 'Evidence-based indication' will be operationally defined as receipt of therapeutic plasmapheresis OR having a diagnosis of liver cirrhosis and being in receipt of a paracentesis. This latter criterion enables identification of patients with spontaneous bacterial peritonitis or large volume ascitic fluid removal.